| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C22H24N2 |
| Molar mass | 316.448 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
Pipequaline (INN; development codePK-8165) is ananxiolyticdrug that was never marketed.[1] It possesses a novelchemical structure that is not closely related to other drugs of this type. The drug has a similar pharmacological profile to thebenzodiazepine family of drugs, but with mainly anxiolytic properties and very littlesedative,amnestic oranticonvulsant effects, and so is classified as anonbenzodiazepine anxiolytic.[2][3][4]
Pipequaline acts as a non-selectiveGABAA receptorpartial agonist.[5][6][7] While its profile of anxiolytic effects without sedation would appear to have potential medical applications, pipequaline has never been developed for medical use and is currently only used in scientific research.